Vascular reactivity and pulmonary hypertension in systemic sclerosis

Rozkovec, A.; Bernstein, Robert; Asherson, Ronald A.; Oakley, Celia M.

doi:10.1002/art.1780260815

Cited by 22 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the presence of 2 -GPI/aCL might be associated with thrombosis. In addition, obliterative vascular disease is a major cause of pulmonary hypertension in SSc [22,23]. Therefore, 2 -GPI/aCL IgG might be closely associated with PH in SSc.…”

Section: Discussionmentioning

confidence: 99%

Measurement of anticardiolipin antibodies by ELISA using β2-glycoprotein I (β2-GPI) in systemic sclerosis

Ihn

Sato

Fujimoto

et al. 1996

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYIn order to determine the prevalence and clinical significance of¯2-GPI-dependent anticardiolipin antibodies (¯2-GPI/aCL) in patients with systemic sclerosis (SSc), serum samples from 80 patients with SSc, 20 patients with systemic lupus erythematosus (SLE), and 120 healthy control subjects were examined by ELISA using purified¯2-GPI. IgG isotype¯2-GPI/aCL was present in eight of 80 patients with SSc (10%), and the presence of¯2-GPI/aCL IgG was significantly correlated with the presence of isolated pulmonary hypertension (PH). Furthermore, levels of¯2-GPI/aCL IgG were significantly correlated with levels of mean pulmonary arterial pressure. These data suggest that IgG isotype¯2-GPI/ aCL might be a serological indicator of the severity of PH in patients with SSc.

show abstract

Section: Discussionmentioning

confidence: 99%

Measurement of anticardiolipin antibodies by ELISA using β2-glycoprotein I (β2-GPI) in systemic sclerosis

Ihn

Sato

Fujimoto

et al. 1996

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Raynaud's is also common in patients with SLE and MCTD and pulmonary hypertension (21,43,48) , but only 10%-14% of the patients with primary pulmonary hypertension have Raynaud's phenomenon (49) . This observation has led to the "pulmonary Raynaud's" hypothesis that vasospasm contributes to the development of pulmonary hypertension (50,51) . Acute hypoxic pulmonary vasoconstriction may be more pronounced in patients with pulmonary hypertension and scleroderma than in patients with primary pulmonary hypertension (52) .…”

Section: Pathogenesismentioning

confidence: 99%

Scleroderma and pulmonary hypertension

Fagan¹,

Badesch²

2003

Rev. Bras. Reumatol.

View full text Add to dashboard Cite

Patients with scleroderma are at increased risk for the development of pulmonary hypertension, and the development of unexplained dyspnea or an isolated decrease in diffusing capacity should prompt evaluation. Echocardiography is often helpful in this situation, with further testing being performed as indicated. Because the prognosis of untreated pulmonary hypertension occurring in the setting of scleroderma is generally quite poor, vigilance is required on the part of physicians following this "at risk" group of patients. The past decade has seen important advances in the treatment of pulmonary arterial hypertension, including intravenous epoprostenol, oral bosentan and subcutaneously infused treprostinil. As new therapies are developed for the treatment of pulmonary arterial hypertension, it is essential that patients with scleroderma-related disease are included in clinical trials.Keywords: scleroderma, pulmonary hypertension, dyspnea. RESUMO

show abstract

“…[2][3][4][5][6][7][8] If so, pulmonary vasodilators may be particularly useful in some patients with connective tissue disease, particularly early in the course of the diseases. [2][3][4][5][6][7][8] If so, pulmonary vasodilators may be particularly useful in some patients with connective tissue disease, particularly early in the course of the diseases.…”

Section: Pulmonary Hypertension Inmentioning

confidence: 99%